🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

522 results for “therapy” Clear

  1. GRANISETRON EXTENDED RELEASE INJECTION (GERSC)

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 2 small molecule terminated

    1 trial

  2. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  3. Glasdegib

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia (AML) Due to Therapy

    phase 2 small molecule active

    1 trial

  4. HYDROXYCARBAMIDE , BEVACIZUMAB , SUNITINIB , OCTREOTIDE , EVEROLIMUS , Lutathera 370 MBq/mL solution for infusion

    Ningbo Cancer Hospital

    Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)

    phase 2 small molecule active

    1 trial

  5. Halneuron

    Dogwood Therapeutics

    Chemotherapy Induced Neuropathic Pain

    phase 2 small molecule active

    1 trial

  6. Herombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

  7. High-Low Dose Radiotherapy

    Jian Li

    Nasopharyngeal Carcinoma (NPC)

    phase 2 other active

    1 trial

  8. Hyperbaric Oxygen Therapy

    Summit Therapeutics

    TBI Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  9. Hypofractionated radiation/chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  10. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy

    phase 2 small molecule active

    1 trial

  11. IMFINZI 50 mg/mL concentrate for solution for infusion., FLUOROURACIL, FOLINIC ACID, OXALIPLATIN

    Ningbo Cancer Hospital

    Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy

    phase 2 small molecule active

    1 trial

  12. INCAGN02385, Retifanlimab (INCMGA00012), INCAGN02390

    Incyte

    In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.

    phase 2 small molecule active

    1 trial

  13. Immunotherapy combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  14. Induction Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN

    phase 2 small molecule active

    1 trial

  15. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  16. Induction therapy of GP(Pomalidomide+Obinutuzumab）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Indolent Lymphoma

    phase 2 small molecule active

    1 trial

  17. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  18. Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

    The George Institute

    Ovarian Cancer

    phase 2 other active

    1 trial

  19. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab

    The George Institute

    Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  20. Isatuximab, DEXAMETHASONE, POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, DEXAMETHASONE, Isatuximab

    Wuhan Createrna Science and Technology Co., Ltd

    Multiple myeloma patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor"

    phase 2 small molecule active

    1 trial

  21. Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  22. Ivonescimab Combined With Chemotherapy

    The First People's Hospital of Lianyungang

    Pretreated Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion., Darleukin, Fibromun

    Philogen S.p.A.

    Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources